The preparation of Sofosbuvir, the potent key component of recent Hepatitis C (HCV) infection therapies, is reported. The process is based on the dynamic kinetic resolution of the stereochemically unstable isopropyl-2-([chloro(phenoxy)phosphoryl]-aminopropanoate (8). A high stereoselectivity was obtained when the right protective group for 3'-OH was chosen. Ester and carbonate-based protective groups gave lower stereoselectivities, but benzyl protection allowed the phosphorylation to occur with a 92:8 ratio in favour of the product with the right configuration at the P-stereogenic centre. Starting from the γ-lactone of 2-deoxy-2-fluoro-2-methylpentonic acid, the synthesis was accomplished in eight steps in 40% overall yield using commercially available reagents, and without any enzymatic or chemical resolution technique.
Cini, E., Barreca, G., Carcone, L., Manetti, F., Rasparini, M., Taddei, M. (2018). Stereoselective Synthesis of Sofosbuvir through Nucleoside Phosphorylation Controlled by Kinetic Resolution. EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2018(20-21), 2622-2628 [10.1002/ejoc.201800158].
Stereoselective Synthesis of Sofosbuvir through Nucleoside Phosphorylation Controlled by Kinetic Resolution
Cini, Elena;Carcone, Luca;Manetti, Fabrizio;Taddei Maurizio
2018-01-01
Abstract
The preparation of Sofosbuvir, the potent key component of recent Hepatitis C (HCV) infection therapies, is reported. The process is based on the dynamic kinetic resolution of the stereochemically unstable isopropyl-2-([chloro(phenoxy)phosphoryl]-aminopropanoate (8). A high stereoselectivity was obtained when the right protective group for 3'-OH was chosen. Ester and carbonate-based protective groups gave lower stereoselectivities, but benzyl protection allowed the phosphorylation to occur with a 92:8 ratio in favour of the product with the right configuration at the P-stereogenic centre. Starting from the γ-lactone of 2-deoxy-2-fluoro-2-methylpentonic acid, the synthesis was accomplished in eight steps in 40% overall yield using commercially available reagents, and without any enzymatic or chemical resolution technique.File | Dimensione | Formato | |
---|---|---|---|
2018_EurJOrgChem_Sofosbuvir.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
1.17 MB
Formato
Adobe PDF
|
1.17 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1054420